Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the ...

However, Novavax has remained a notable player in this field. The biotech recently said that its updated vaccine received EUA ...

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

Novavax Inc. closed $11.08 short of its 52-week high ($23.86), which the company achieved on June 6th.

Sept. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 ...

Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know.

Novavax Inc. closed $10.66 short of its 52-week high ($23.86), which the company reached on June 6th. Supported by ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

Vaccine maker Novavax (NASDAQ: NVAX) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (NASDAQ: SNY), sending its stock price soaring.

Of course, Novavax is planning to develop its own products. The company is working on two products: a stand-alone influenza vaccine and a combined COVID/flu vaccine. Novavax plans to start phase 3 ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.61 which represents a slight increase of $1.69 or 14.18% from the prior close of $11.92. The stock opened at $11.87 and touched a ...